Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 5/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1477128 | 0.85 | HSD17B10 (0.33) | GRM5GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL30125788 | 0.85 | HSD17B10 (0.33) | GRM5GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL14881372 | 0.82 | TDP1 (0.38) | ALDH1A1GRM5GABRA1GABRG2GABRB3 | |
| SCHEMBL1477690 | 0.82 | GRM5 (0.43) | GRM5GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL23851284 | 0.79 | GRM5 (0.36) | ALDH1A1GRM5HDAC1HDAC6GABRA1 | |
| SCHEMBL6948487 | 0.79 | CYP3A4 (0.43) | ALDH1A1GRM5GABRA1GABRG2GABRB3 | |
| SCHEMBL20929147 | 0.79 | LOX (0.32) | HDAC1HDAC6LOX | |
| SCHEMBL29353640 | 0.78 | CYP3A4 (0.42) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL20929091 | 0.78 | CYP3A4 (0.42) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL19748358 | 0.78 | KDM1A (0.33) | GRM5GABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005058849-A1 | NEW DIPEPTIDYL PEPTIDASE IN INHIBITORS; PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LTD. (US) | 2005-06-30 | — | — | WO | claimed |
| US-20250263411-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER INC. (US) | 2025-08-21 | — | — | US | disclosed |
| CN-117561255-A | 3, 4-dihydro-2, 7-naphthyridine-1, 6 (2H, 7H) -dione compounds as MEK inhibitors | 辉瑞公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-3481819-B1 | COMPOUNDS AND THEIR USE FOR REDUCING URIC ACID LEVELS | ACQUIST LLC (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-109476642-B | Compounds and their use for reducing uric acid levels | 阿奎斯特有限责任公司 | 2022-01-25 | — | — | CN | disclosed |
| US-20210236495-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2021-08-05 | — | — | US | disclosed |
| US-11020397-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200268757-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200197393-A9 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC | 2020-06-25 | — | — | US | disclosed |
| US-10688095-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2020-06-23 | — | — | US | disclosed |
| US-20130096113-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| US-7078438-B2 | N-(4 substituted phenyl)-anthranilic acid hydroxamate esters | WARNER-LAMBERT COMPANY (US) | 2006-07-18 | — | — | US | disclosed |
| US-20050137263-A1 | N-(4 substituted phenyl)-anthranilic acid hydroxamate esters | WARNER-LAMBERT COMPANY, LLC | 2005-06-23 | — | — | US | disclosed |
| US-6891066-B2 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | WARNER-LAMBERT COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| US-20050059710-A1 | Diphenylamino ketone derivatives as MEK inhibitors | PFIZER INC | 2005-03-17 | — | — | US | disclosed |
| WO-2005007616-A1 | DIPHENYLAMINO KETONE DERIVATIVES AS MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| EP-1467968-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | Warner-Lambert Company LLC (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040006245-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | REWCASTLE GORDON WILLIAM (NZ) | 2004-01-08 | — | — | US | disclosed |
| WO-2003062191-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096113-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | FLT3, PDGFRB, PDGFRA | ALDH1A1 1363/4885GRM5 1666/4885CA12 3823/4885 |
| US-10688095-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, UGT2B7 | ALDH1A1 95/4885GRM5 1370/4885CA12 1523/4885 |
| US-20050004186-A1 | MEK inhibiting compounds | MAPK1, MAP3K1, MAPK3 | ALDH1A1 1628/4885GRM5 2529/4885CA12 4885/4885 |
| US-20210236495-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | ALDH1A1 226/4885GRM5 2821/4885CA12 1614/4885 |
| US-20200268757-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | ALDH1A1 226/4885GRM5 2821/4885CA12 1614/4885 |
| US-20050059710-A1 | Diphenylamino ketone derivatives as MEK inhibitors | BRAF, RAF1, MAP3K1 | ALDH1A1 892/4885GRM5 3503/4885CA12 4753/4885 |
| US-20250263411-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | NRAS, KRAS, BRAF | ALDH1A1 1249/4885GRM5 3666/4885CA12 4729/4885 |
| US-20050137263-A1 | N-(4 substituted phenyl)-anthranilic acid hydroxamate esters | PAH, EGLN3, PAOX | ALDH1A1 377/4885GRM5 1990/4885CA12 373/4885 |
| US-11020397-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, UGT2B7 | ALDH1A1 95/4885GRM5 1370/4885CA12 1523/4885 |
| US-20040006245-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | HCAR2, EGLN3, AADAC | ALDH1A1 436/4885GRM5 1632/4885CA12 440/4885 |
| US-20200197393-A9 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | ALDH1A1 226/4885GRM5 2821/4885CA12 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.